AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01665157 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: low volume 1.5L PEG-ELS
Description: Low volume PEG-ELS
Study NCT02915757 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EDOR test
Description: The ElectroDermal Orienting Reactivity (EDOR) specifically is optimized for the detection of electrodermal hyporeactivity.~The EDOR investigation last about 30 min. The EDOR Test Data is sent immediately after each EDOR Test for each Test Person to a Company named EMOTRA for blind analyses. The EDOR Test Report may change the basis for the assessment and a new risk assessment may be needed to be done.~Blood sample and clinical assessment
Study NCT01057238 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intensive Communication System
Description: Regular family meetings once a week, using a standard protocol
Study NCT03927469 — intervention group
Intervention type: OTHER
Intervention: age, sex, hemiplegic side, stroke duration, First hospitalisation duration (day)
Description: This is a retrospiective descriptive study
Study NCT02901067 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aspirin and Rosuvastatin
Description: Patients assigned to the intervention arm will receive the standard of care anti-coagulation plus the combination experimental drugs (20mg of rosuvastatin daily and 325mg of aspirin) daily either orally or via feeding tube.
Study NCT04016948 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Probe-based confocal laser endomicroscopy optical biopsy
Description: In the pCLE group, after intravenous injection of fluorescein, the optical biopsy will be performed, using a confocal miniprobe, to exam the rectal mucosa when the rectum transection is ready. The raters will analyse the CLE images to determine whether the distal margin is positive. In the IFS group, intra-operative frozen section will be performed at the site of distal margin after the rectum transection.
Study NCT02901067 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (for Aspirin and Rosuvastatin)
Description: Patients assigned to the control group will receive the standard of care anti-coagulation plus identical-looking placebos either orally or via feeding tube.
Study NCT04016948 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Intra-operative frozen section
Description: In the pCLE group, after intravenous injection of fluorescein, the optical biopsy will be performed, using a confocal miniprobe, to exam the rectal mucosa when the rectum transection is ready. The raters will analyse the CLE images to determine whether the distal margin is positive. In the IFS group, intra-operative frozen section will be performed at the site of distal margin after the rectum transection.
Study NCT03623087 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: SIMPLE
Study NCT03623087 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: SIMPLE
Study NCT03623087 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide (VP-16)
Description: SIMPLE
Study NCT03710382 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Walking epidural
Description: Parturients in spontaneous or induced labor will receive combined spinal-epidural analgesia (CSE) using an infusion of bupivacaine 0.0625% and fentanyl 2 mcg/mL and will be encouraged to walk a minimum of 15 minutes every hour during the first stage of labor.
Study NCT03660332 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Infusion of a liquid meal intraduodenally
Description: Infusion of IL-6/NaCL before a liquid meal intraduodenally
Study NCT03623087 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ifosfamide
Description: SIMPLE
Study NCT03623087 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: SIMPLE
Study NCT03623087 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: L-asparaginase
Description: SIMPLE
Study NCT02241941 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daptomycin
Study NCT03660332 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Infusion of a liquid meal intraduodenally
Description: Infusion of IL-6/NaCL before a liquid meal intraduodenally
Study NCT04037163 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Fractional flow reserve, Coronary CT angiography
Description: Coronary CT angiography was performed as part of routine clinical practice for patients with suspected coronary artery disease and the decision to perform coronary CT angiography before invasive angiography was at the judgment of the physicians in charge.
Study NCT03877601 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab-IRDye800CW
Description: Topical administration of Bevacizumab-IRDye800CW during the endoscopic procedure.
Study NCT03877601 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Fluorescence endoscopy
Description: Device: Molecular Fluorescence Endoscopy platform A flexible fluorescence fiber-bundle is attached to a fluorescence camera platform to enable the detection of fluorescence signals. The fluorescence fiber-probe is inserted through the standard working channel of the standard clinical endoscope.
Study NCT03884530 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ticagrelor (Brilique) 90
Description: Drug name Brilique 90 ml Drug form tablet
Study NCT03884530 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aspirin 75mg
Description: Drug name Aspirin 75 ml Drug form tablet
Study NCT01532960 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: poly-ICLC
Description: poly-ICLC
Study NCT01532960 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 9 Peptides from Her-2/neu, CEA, & CTA
Description: 9 synthetic peptides derived from Her-2/neu, CEA \& CTA derived breast cancer proteins.
Study NCT01532960 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Peptide-tet
Description: A class II MHC-restricted helper peptide derived from tetanus toxoid protein.
Study NCT00282399 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Subcutaneous Decitabine
Study NCT04060875 — intervention group
Intervention type: DEVICE
Intervention: Karuna Labs Virtual Reality Software
Description: The subjects will engage in the three therapeutic modules: laterality, motor imagery, and 'mirroring.' The decision of which module to employ will be based on the subject's readiness and comfort on a case-by-case basis. A subject visit can be expected to last 40 minutes, with enough time to complete PHQ-9, and to accustom to the virtual reality setup by playing in a non-therapeutic virtual environment should they choose to do so. Time in the virtual reality is expected to last approximately 20 minutes per session.
Study NCT01892059 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Segmental artery clamping
Description: Laparoscopic partial nephrectomy with segmental artery clamping will be performed for patients enrolled in this group.
Study NCT01892059 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Main renal artery clamping
Description: Laparoscopic partial nephrectomy with main renal artery clamping technique will be performed for patients enrolled in this group.
Study NCT04216030 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High Fe IP meal labelled with Fe-58
Description: 500 gram steamed, mashed OFSP high Fe with 0.33 mg FeSO4-58 daily for 10 days
Study NCT04216030 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control OFSP meal labelled with Fe-57
Description: 500 gram steamed, mashed OFSP control with 0.33 mg FeSO5-57 daily for 10 days
Study NCT02231710 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BPX-501 and Rimiducid
Description: Single administration of BPX-501 T cells post partially-mismatched, related T cell depleted HCT followed by Rimiducid infusion on day 7
Study NCT03454971 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MinOS protocol
Description: At Day 1, Cycle 1 and 2 of the patient's oral therapy :~* Consultation with a hospital pharmacist~* Consultation with a nurse care coordinator~* Consultation with the patient's oncologist/hematologist~During this multidisciplinary consultation, will be reviewed :~* potential medical interactions,~* possible adverse effects of therapy,~* information on the prescribed drug,~* informations on the patient's lifestyle, ...~At day 8 and 15, cycle 1 and 2 :~Phone call from the nurse care coordinator during which will be reported the adverse effects and adherence issues. If needed, the nurse care coordinator can provide complementary information about the treatment.~The MINOS protocol follow up will end with a consultation with the patient's oncologist/hematologist, at day 1 cycle 3.
Study NCT01569828 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LCZ696A
Study NCT01569828 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LCZ696A
Description: once daily administration of 400 mg LCZ696 for 5 days
Study NCT03726255 — intervention group
Intervention type: PROCEDURE
Intervention: Mesenchymal Stem Cell injection
Description: curettage, closure of the internal opening (IO) and cell injection in IO (50%) and fistula tract (50%)
Study NCT03827213 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Exparel
Description: A shot of long acting local anesthetic for post operative pain management
Study NCT03827213 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Indwelling Interscalene Catheter
Description: ropivacaine, given through a catheter inserted between the shoulders
Study NCT00686036 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vandetanib
Description: 300 mg orally, once daily for up to 18 months
Study NCT00686036 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT02386410 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Group parent training for anxious parents
Study NCT02386410 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Internet delivered parent training for anxious parents
Study NCT02435979 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: hand therapy
Description: Treatment can include stretching, motion, and strengthening exercises. As the patients endurance and strength increased the repetitions and/or resistance of these exercises will increase. Modalities for pain control and tissue mobility, and bracing or splinting if necessary. All treatments for the traditional hand therapy treatment group will occur seated at the hand therapy treatment table.
Study NCT02435979 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: hand therapy
Description: Treatment can include stretching, motion, and strengthening exercises. As the patients endurance and strength increased the repetitions and/or resistance of these exercises will increase. Modalities for pain control and tissue mobility, and bracing or splinting if necessary. All treatments for the traditional hand therapy treatment group will occur seated at the hand therapy treatment table.
Study NCT02435979 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Proximal Strengthening
Description: Patients will perform a standardized proximal strengthening protocol consisting of cervical, periscapular, and shoulder strengthening exercises. Depending on the pace and guidance needed for these exercises 25-30 minutes will be spent on proximal strengthening exercises. As the patients endurance and strength increased the repetitions and/or resistance of these exercises will increase.
Study NCT04118231 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dry needling
Description: Group 1: Dry needling Group 2: static stretching Group 3: IASTM
Study NCT02202018 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Active KT intervention
Description: 1. Provider \& patient-directed infographics educating patients about home dialysis will be displayed in prominent clinic wall space~2. Educational white board presentations promoting home dialysis~3. Each clinic will receive reports outlining their current use of home dialysis in incident ESRD patients compared with provincial \& national averages~4. A Canadian version of the MATCH D tool will be provided to clinic staff, to help evaluate patient appropriateness for home dialysis.~5. Each clinic will receive an in-person visit from one of the study investigators/collaborators detailing the benefits of home dialysis, and the educational tools being offered to support care within their clinic.
Study NCT02363582 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: formula
Description: An infant formula contains prebiotics and lactoferrin
Study NCT03405285 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Connected Catheter
Description: The Connected Catheter is a fully internal, urethral-indwelling urinary prosthesis designed for improved bladder management in males with urinary retention disorders requiring catheterization, including neurogenic lower urinary tract dysfunction (NLUTD - e.g. due to spinal cord injury). The CoCath is a sterile, single-extended-use device that resides fully internally to the male lower urinary tract (urethra + bladder neck) for an intended service life of up to 29 days per Catheter.
Study NCT01006707 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Ondansetron
Description: In this cross-over study, the blinded patient will receive saline placebo in one session and ondansetron in the other. The order is decided with a randomization table. If ondansetron is randomly chosen, an 8mg IV Bolus will be given at the start of the study for 30 minutes by the unblinded investigator.
Study NCT03211156 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amoxicillin
Description: Amoxicillin is an aminopenicillin antibiotic
Study NCT03211156 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT00679523 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AN2690 Solution, 5.0%
Description: Once daily application for 180 days
Study NCT03581812 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Intervention snack 1
Description: To be eaten instead of regular snacks twice a day for 4 weeks.
Study NCT03581812 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Intervention snack 2
Description: To be eaten instead of regular snacks twice a day for 4 weeks.
Study NCT03581812 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Control snack
Description: To be eaten instead of regular snacks twice a day for 4 weeks.
Study NCT04584229 — intervention group
Intervention type: OTHER
Intervention: Intervention
Description: Intervention: comprehensive individual or collective interview, recorded and transcribed
Study NCT03381768 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PD-L2 peptide
Description: 100 ug PD-L2 peptide dissolved in DMSO and water mixed with 500ul montanide.
Study NCT03381768 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PD-L2 and PD-L1 peptide
Description: 100 ug PD-L2 peptide and 100ug PD-L1 peptide dissolved in DMSO and water mixed with 500ul montanide.
Study NCT04000295 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apatinib
Description: Subjects receive Apatinib orally, Dosage form: tablet, Strength: 375 mg/d
Study NCT04000295 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: Subjects receive Etoposide capsule orally, d1-14, q3w, Dosage form: capsule, Strength: 50 mg/d
Study NCT03205956 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levodopa
Description: At least 1 hour after 200mg carbidopa p.o., each subject will receive an intravenous solution of levodopa in saline at a rate based on age and body mass according to the final dose described in Black et al 2003.The total dose for a 70-year-old, 70kg subject will be approximately 65mg.~Subjects with untreated PD will then take 6 ± 1 weeks of clinically dosed oral carbidopa-levodopa tablets for clinical purposes and then repeat the carbidopa plus intravenous levodopa dose as above.
Study NCT01600456 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Prolonged exposure (PE)
Description: PE will include 10 weekly sessions of individual cognitive behavioral therapy.
Study NCT04000295 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel
Description: Subjects receive Weekly Paclitaxel, intravenously, d1, d8, d15, q3w, Dosage form: injectable, Strength: 80 mg/m2
Study NCT01600456 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: PE plus Sertraline
Description: PE plus sertraline will include 10 weeks of prolonged exposure therapy plus sertraline. The sertraline dose will be up to 200 mg daily for 10 weeks. There will also be frequent meetings with study psychiatrist. PE will be provided 1x weekly for 10 weeks.
Study NCT04512066 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO6889450
Description: Participants will receive oral RO6889450 QD.
Study NCT04512066 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will receive oral placebo QD.
Study NCT04512066 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Risperidone
Description: Participants will receive oral risperidone QD.
Study NCT02883062 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Given IV
Study NCT02883062 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Biospecimen Collection
Description: Undergo collection of blood samples
Study NCT01224093 — intervention group
Intervention type: DRUG
Intervention: Chemotherapy
Description: as prescribed
Study NCT01224093 — intervention group
Intervention type: DRUG
Intervention: rituximab [MabThera/Rituxan]
Description: as prescribed
Study NCT03661242 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Physical activity
Description: Patients in shared care arm has regular combined visits with Oncologist and Clincal Exercise Physiologist (CEP). Individual physical activity plan developed by CEP for patients in shared care arm.
Study NCT03625466 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LUM/IVA
Description: FDC tablets or granules for oral administration.
Study NCT03625466 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LUM/IVA
Description: FDC granules for oral administration.
Study NCT03625466 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo matched to LUM/IVA for oral administration.
Study NCT03764397 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Prehabilitation for behavioural change
Description: The 4-week prehabilitation educational programme will consist of a meeting for one session (approximately 1 - 1.5 hours) per week. This behavioural change programme will involve a mixture of interactive and didactic sessions, facilitated by a physiotherapist, psychologists, and other health professionals. The purpose of the initial prehabilitation programme is to gain participant 'buy-in' to the programme, to assist participants engage with exercise, to help participants overcome barriers to exercise and improve self-efficacy for exercise. The prehabilitation phase will also enable participants to understand why and how to perform gentle self-paced exercise. After the prehabilitation programme, participants will be advised to engage in a 6-week gentle self-paced walking programme; i.e., a simple pedometer-driven walking programme with weekly telephone support.
Study NCT02737943 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Moist Exposed Burn Ointment (MEBO)
Description: is a registered USA patented formulation since 1995. MEBO is pure herbal, natural in origin, containing beta-sitosterol phellodendron amurense, scutellaria baicalensis, coptis chinensis, pheretima aspergillum, Beeswax and sesame oil. 15, 19 The pharmacological effects are attributable to: beta-sitosterol, isolated from phellodendron amurense, flavonoids mainly baicalin isolated from scutellaria baicalensis, alkaloids mainly berberine, isolated from coptis chinensis, Beeswax and sesame oil.
Study NCT02737943 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Zagazig
Description: Standard care is an antibiotic ointment in combination of analgesic for relief of pain.
Study NCT01665625 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: regional interventional chemotherapy group
Description: The patients in experimental group were monitored by X-ray imaging. A 0.038 super-sliding guide wire was inserted after successful puncture, and when site of the pancreatic carcinoma was reconfirmed by conventional angiography, a 5F cobra catheter was used to place the port-catheter drug delivery system in the celiac artery (pancreatic head) or the hepatic artery (pancreatic body and tail). Finally, the port-catheter was embedded under the left upper chest.
Study NCT00713258 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Parathyroid hormone (PTH) (1-84)
Description: 100 µg PTH(1-84) daily
Study NCT00713258 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Alendronate
Description: 70 mg alendronate weekly
Study NCT04550689 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Bone graft
Description: Bone grafts produced by Straumann LLC
Study NCT03383640 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Active exercises
Description: Active flexion movements every waking hour of the replanted digits
Study NCT03017378 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: TB/FLU-01L
Description: TB / FLU-01L (intranasal application)
Study NCT03017378 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: TB/FLU-01L
Description: TB/FLU-01L (sublingual application)